A Mechanism of Action Study of Intratumoral or Intravenous Dosing of Enadenotucirev, an Oncolytic Adenovirus, in Patients with Colon, Lung, Bladder and Renal Carcinoma Undergoing Resection of Primary Tumour

Rocio García-Carbone1, Valentina Bore2, Ignacio Durán3, Marta Gil-Martin4, Marta Espinosa5, Ramon Salazar3, Antonio Collés3, Monica Jurado6, Brian Champion7, Simon Akers6, Kerry Fisher6, John Beadle8, Gillian Power9, Mary McEvoy-Johnson9, Christopher Ellis9, Christine Wilbourn-Bone7, Emilio Carbonero3, Isabel Carbonero3, Cristina Carbonero3

1. Hospital Universitario Virgen del Rocio, Seville, Spain, 2. START Madrid, Centro Integral Oncológico Daina Camel, Madrid, Spain, 3. Early Clinical Research Unit, Instituto Danca 3. Oncología, 4. Hospital Infanta Leonor, Madrid, Spain, 5. Pfizer Therapeutics Limited, Milton Park, Abingdon, United Kingdom

Clinical Trial Information: EUDRACT 2013-000386-11

Analysis of Nanostar data used the rCountPan cancer immune gene profiling probe set of 770 genes. For each gene in each sample, the expression level was measured and then divided by the mean of the 5 control CC samples for that gene. The number of genes whose expression level were either 2 or 1.5-fold different for each of the samples were counted as genes that may be potentially regulated in response to treatment with EnAd. Data are expressed as total number and as % of the full 770 gene set, see Table 2.